Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the combination of topical minoxidil 5% and betamethasone valerate 0.1% achieved slightly higher depigmentation in vitiligo of hair-bearing areas but did not show significant improvement over betamethasone valerate alone.

This review examines recent advancements in topical formulations for alopecia treatment, but it reports no new clinical results, emphasizing potential strategies to enhance drug delivery to the scalp.

In this study, eight Chinese patients with alopecia areata showed hair regrowth following combination therapy with a nonablative laser and topical minoxidil, with most patients not experiencing relapse after one year, suggesting a promising alternative treatment without significant side effects.

This systematic review concluded that 5 mg of oral finasteride per day could be an effective and safe treatment for female pattern hair loss in normoandrogenic women, particularly when combined with other medications.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

In this study, topical minoxidil did not show an antiandrogenic effect on androgen-dependent cutaneous structures in the golden Syrian hamster, suggesting it likely does not have this role in humans either.

This article discusses the formulation of nanoemulsion systems as advanced drug delivery mechanisms, but it reports no new clinical findings.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

This study found that adapalene-loaded solid lipid microparticles may enhance targeted drug delivery into sebum due to their similarity to sebum components, although both this formulation and a standard cream showed equivalent follicular penetration.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

This article suggests that a topical sulfonylurea drug may inhibit excessive hair growth caused by diazoxide without affecting its beneficial effects on beta cells, potentially offering a treatment for various forms of hypertrichosis and hirsutism.

In this study, the researchers describe a case of feline demodicosis that presented with dermatological lesions but lacked the typical signs of pruritus or overgrooming, and they report successful off-label treatment using a single spot-on application of fluralaner.

This study found that a novel 15% topical minoxidil solution achieved a clinically significant hair regrowth response in 60% of women with female pattern hair loss who did not respond to 5% minoxidil, without increasing adverse events.

In this review, researchers discussed the anti-inflammatory and immunomodulatory properties of metformin and hypothesized that its topical application could benefit those with alopecia areata, given its effects on immune pathways, hair regrowth, and autoimmune disease management.

This study reports that a new topical solution, AB-102, containing a high concentration of a weak α1 agonist, significantly reduces hair shedding during brushing by up to 77% without causing cardiac or hemodynamic adverse events.

This study found that a novel topical dutasteride lotion, FOL100, demonstrated excellent safety, tolerability, and usability with promising signs of clinical benefit for mild-to-moderate male pattern baldness.

In this study, researchers developed a novel topical gel combining minoxidil and JAK inhibitor tofacitinib, which effectively enhanced hair follicle growth and reduced local inflammation in mice with alopecia areata, suggesting a new approach for treating this condition.

This proof-of-concept study suggests that the new topical treatment regimen TH07 may offer effective hair growth results in men with androgenic alopecia, using a combination of finasteride, latanoprost, and minoxidil, supported by animal models and clinical studies.

This case study describes a unique instance of unilateral steroid-induced rosacea-like dermatitis likely due to long-term localized use of topical corticosteroids, emphasizing the need for careful application and thorough histopathological analysis.

This case report describes a Japanese woman with unilateral steroid-induced rosacea-like dermatitis attributed to long-term topical corticosteroid use, highlighting the significance of appropriate steroid application and histopathological evaluation for facial erythematous nodules.

This study found that using a non-invasive multielectrode array for gene electrotransfer in hairless guinea pigs increased gene expression in the epidermis significantly, with minimal skin changes observed.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

In this study, the novel 5% minoxidil formulation significantly increased scalp hydration and decreased redness in Indian men with androgenetic alopecia compared to alcohol-based formulations.

This study found that IMT-P8, a novel cell-penetrating peptide, effectively facilitated the dermal delivery of proteins and peptides in mouse skin and cell lines, suggesting potential for topical applications in cosmetics and skin diseases.

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

This article discusses using topical tretinoin with intralesional triamcinolone acetonide for alopecia areata in northern Saudi Arabia, but it reports no new clinical findings.

This study suggests that LOYON® is safe, well tolerated, and effective in reducing scaling from cradle cap in infants and children without causing spot bleedings.

This study found that minoxidil pretreatment in rat skin flaps enhanced angiogenesis and increased flap survival compared to untreated flaps, but was less effective at reducing necrosis than surgical delay.

This study observed significant improvements in hair loss and hair density among adults using USPlus DERM Topical serum daily for 12 weeks, with 90.9% of participants noticing better hair loss/density and rating satisfaction at an average of 7.7 out of 10.

In this study, topical tofacitinib significantly promoted hair regrowth in mice, outpacing both minoxidil and controls over 21 days, with findings suggesting increased VEGF levels and decreased inflammation as possible mechanisms.